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MaOBJECTIVES The aim of this study was to investigate N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels and
recent heart failure (HF) hospitalization as predictors of future events in heart failure – preserved ejection fraction (HF-PEF).
BACKGROUND Recently, doubt has been expressed about the value of a history of HF hospitalization as a predictor of
adverse cardiovascular outcomes in patients with HF and HF-PEF.
METHODS We estimated rates and adjusted hazard ratios (HRs) for the composite endpoint of cardiovascular death or
HF hospitalization, according to history of recent HF hospitalization and baseline NT-proBNP level in the I-PRESERVE
(Irbesartan in Heart Failure with Preserved systolic function) trial.
RESULTS Rates of composite endpoints in patients with (n ¼ 804) and without (n ¼ 1,963) a recent HF hospitalization
were 12.78 (95% conﬁdence interval [CI]: 11.47 to 14.24) and 4.49 (95% CI: 4.04 to 4.99) per 100 person-years,
respectively (HR: 2.71; 95% CI: 2.33 to 3.16). For patients with NT-proBNP concentrations >360 pg/ml (n ¼ 1,299), the
event rate was 11.51 (95% CI: 10.54 to 12.58) compared to 3.04 (95% CI: 2.63 to 3.52) per 100 person-years in those with
a lower level of NT-proBNP (n ¼ 1468) (HR: 3.19; 95% CI: 2.68 to 3.80). In patients with no recent HF hospitalization
and NT-proBNP #360 pg/ml (n ¼ 1,187), the event rate was 2.43 (95% CI: 2.03 to 2.90) compared with 17.79 (95%
CI: 15.77 to 20.07) per 100 person-years when both risk predictors were present (n¼ 523; HR: 6.18; 95% CI: 4.96 to 7.69).
CONCLUSIONS Recent hospitalization for HF or an elevated level of NT-proBNP identiﬁed patients at higher risk
for cardiovascular events, and this risk was increased further when both factors were present. (J Am Coll Cardiol HF
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479AB BR E V I A T I O N S
AND ACRONYM S
HF = heart failure
HF-PEF = heart failure with
preserved ejection fraction
NYHA = New York Heart
Association
NT-proBNP = N-terminal pro–
B-type natriuretic peptideA lthough several studies have shown that pre-vious hospitalization for worsening heartfailure (HF), especially if recent, is a power-
ful predictor of future nonfatal and fatal cardiovascu-
lar (CV) events in patients with HF and reduced
ejection fraction (HF-REF) (1–3), the TOPCAT (Treat-
ment of Preserved Cardiac Function with an Aldoste-
rone Antagonist Trial) (4) cast doubt upon that
relationship in patients with heart failure with pre-
served ejection fraction (HF-PEF). There were 2
enrollment strata in TOPCAT: patients were eligible
for inclusion on the basis of a hospitalization within
the previous year, not necessarily for HF but during
which they received treatment for it (n ¼ 2,464), or
alternatively, by having an elevated plasma concen-
tration of natriuretic peptide within the previous 60
days (n ¼ 981). The rate of the primary composite
endpoint of CV death, hospitalization for HF, or
resuscitation from cardiac arrest (the latter was a mi-
nor component of the composite) was lower in the
stratum of patients recently hospitalized (6.0 per 100
patient years in the placebo group) than in the natri-
uretic peptide stratum (8.5 per 100 patient years in
the placebo group) (4). Moreover, there was an interac-
tion between enrollment stratum and treatment effect
(p < 0.01) whereby spironolactone appeared to reduce
the primary endpoint in patients included on the basis
of a natriuretic peptide measurement (placebo-to-spi-
ronolactone hazard ratio [HR] of 0.65; 95% conﬁdence
interval [CI]: 0.49 to 0.87) but not in those randomized
on the basis of prior hospitalization (HR: 1.01; 95% CI:
0.84 to 1.21). These ﬁndings have raised concerns
about the value of the patient’s medical history of HF
hospitalization as a means of enhancing diagnostic
certainty and predicting event rates in trials of HF-
PEF (5). To investigate this issue further, we examined
the relationships of recent HF hospitalization prior to
inclusion and N-terminal pro B-type natriuretic pep-
tide (NT-proBNP) levels assessed at baseline with
event rates in the I-PRESERVE (Irbesartan in Heart
Failure with Preserved systolic function) trial (6).
METHODS
I-PRESERVE examined the effects of the angiotensin
II receptor antagonist irbesartan on morbidity and
mortality in patients with HF-PEF; outcomes of pa-
tients randomly assigned to receive irbesartan did not
differ from those of patient who received placebo (6).
In the present study, we analyzed clinical outcomes
of HF hospitalization and CV death according to
baseline NT-proBNP concentration, history of recent
hospitalization for HF, and combinations of those
factors.PATIENTS. The rationale, design, and results
from I-PRESERVE have been described pre-
viously in detail (7–9). The trial enrolled
4,028 patients with left ventricular ejection
fraction of at least 45% who were $60 years
of age and had HF symptoms corresponding
to New York Heart Association (NYHA) func-
tional classes II to IV. Patients in NYHA
functional class II were required to have had a
hospitalization for HF within 6 months before
enrollment.
Although most patients enrolled in I-PRESERVE
had their concentration of NT-proBNP measured at
their randomization visit, the result was not available
to investigators at the time of enrolment, unlike
TOPCAT, and this measurement was not used to
determine study eligibility (9).
We restricted our main analysis to patients who
were in NYHA functional class III or IV at baseline and
who had had NT-proBNP concentration measured
(Figure 1). We excluded patients in NYHA functional
class II from the main analysis because they were all
required to have a recent HF hospitalization. How-
ever, in a sensitivity analysis, we carried out the same
analyses in all patients with a NT-proBNP measure-
ment, regardless of NYHA functional class.
We report baseline characteristics of patients ac-
cording to the presence or absence of HF hospitali-
zation in the 6 months prior to study inclusion and
baseline level of NT-proBNP, dichotomized at 360
pg/ml (the entry threshold for TOPCAT). In the
sensitivity analysis, we dichotomized NT-proBNP at
300 pg/ml.
OUTCOMES. We studied the composite outcome of
CV death or HF hospitalization, as well as each of the
components of this composite separately. Deaths and
hospitalizations were adjudicated by an independent
endpoint committee.
STATISTICAL ANALYSES. Baseline characteristics are
mean  SD for continuous variables and frequencies
and percentages for categorical variables. Differences
in baseline characteristics according to recent hospi-
talization for HF and NT-proBNP levels were assessed
using a chi-square test for categorical covariates and
either 2-sided Student t tests or analyses of variance for
continuous variables, as appropriate. Incidence rates
of the outcomes of interest are presented according to
100 person-years, and the risk of HF hospitalization,
CV death, and composite outcome were estimated as
HRs in age- and sex-adjusted Cox regression models;
and likelihood ratio tests were conducted comparing
models with and without inclusion of recent HF
hospitalization and NT-proBNP levels. In addition,
FIGURE 1 Flow Chart of the Study Population
Flow diagram for patients analyzed. Because patients who were in New York Heart As-
sociation (NYHA) functional class II (n ¼ 712) required hospitalization for heart failure
(HFH) in the 6 months before randomization, we restricted our main analysis to patients
who were in NYHA functional class III or IV (n ¼ 3,416). Of these, 649 patients did not have
N-terminal pro–B-type natriuretic peptide (NT-proBNP) measurement. As a result, 2,767
patients were eligible for primary analysis. These patients were dichotomized according to
whether they had a history of recent heart failure hospitalization (within 6 months) and
whether they had a plasma NT-proBNP concentration of >360 pg/ml.
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480we assessed risk estimates in a multivariate analysis
previously validated for the I-PRESERVE study (8),
which included adjustments for age, sex, body mass
index, ejection fraction, heart rate, systolic blood
pressure, ischemic cause, congestion on radiographs,
kidney function, blood urea nitrogen level, and
neutrophil count and history of atrial ﬁbrillation,
myocardial infarction, diabetes, and stroke/transient
ischemic attack.
Analyses were repeated using the 4 speciﬁc com-
binations of the 2 risk predictors as a categorical
variable: 1) no recent hospitalization for HF plus NT-
proBNP #360 pg/ml (reference); 2) no recent hospi-
talization for HF plus NT-proBNP>360 pg/ml;
3) recent hospitalization for HF plus NT-proBNP #360
pg/ml; and 4) recent hospitalization for HF plus
NT-proBNP >360 pg/ml. In a sensitivity analysis
including NYHA II patients, the same groups were
created using an NT-proBNP cutpoint of 300 pg/ml.
We also performed a subgroup analysis of patients
with atrial ﬁbrillation to assess whether the prog-
nostic value of elevated NT-proBNP (>360 pg/ml) was
similar or different in these patients.
We did not include randomized treatment in our
model because irbesartan had no effect on anyoutcome in I-PRESERVE. All p values are 2-sided, and
a p value of <0.05 was considered signiﬁcant. All
analyses were performed separately for each dataset,
using Stata version 11 software (Stata Corp., College
Station, Texas).
RESULTS
Characteristics of the patients analyzed are listed in
Table 1. Patients are grouped according to history of
HF hospitalization in the previous 6 months and
NT-proBNP concentrations lower and higher than 360
pg/ml.
PATIENTS WITH RECENT HF HOSPITALIZATION
COMPARED TO THOSE WITHOUT. Of the 2,767 pa-
tients included in the present analyses, 804 (29%)
had a history of recent HF hospitalization. There were
some notable differences compared to patients
without recent HF hospitalization. Patients with
recent HF hospitalization were slightly older (72 vs. 71
years of age), had a lower mean estimated glomerular
ﬁltration rate (eGFR) and twice the prevalence of
atrial ﬁbrillation (AF), and greater use of diuretic
medicine, mineralocorticoid receptor antagonists,
and beta-blockers. Their median level of NT-proBNP
was signiﬁcantly higher than in those without a his-
tory of recent HF hospitalization (609 vs. 254 pg/ml,
respectively).
PATIENTS WITH AN ELEVATED NT-proBNP LEVEL
COMPARED TO THOSE WITHOUT. Baseline NT-
proBNP was >360 pg/ml in 1,299 patients (47%). Pa-
tients with an elevated NT-proBNP level were older
(mean age 73 vs. 70 years of age), more likely to be
male (44% vs. 34%, respectively), and had markedly
lower mean eGFR (63 vs. 74 l/min/1.73m2, respec-
tively). They were also more likely to have ischemic
heart disease (31% vs. 22%, respectively) and had a 4-
fold higher prevalence of AF (44% vs. 10%, respec-
tively) compared to patients with NT-proBNP #360
pg/ml. All other comorbidities were also more com-
mon in patients with higher NT-proBNP levels, and
use of all medications listed was more frequent in
these patients, with the exception of calcium channel
blockers.
Rates of the composite endpoint of HF hospitali-
zation and CV death are presented in Table 2 and
Figure 2. This composite outcome occurred in 674
patients (24%) overall, with a rate per 100 patient
years of 6.56 (95% CI: 6.08 to 7.07).
OUTCOMES ACCORDING TO HISTORY OF HF
HOSPITALIZATION. In a sex- and age-adjusted Cox
regression model, patients with recent HF hospi-
talization were more than twice as likely to
TABLE 1 Baseline Characteristics According to Previous Hospitalization for Heart Failure and NT-proBNP Levels
All Patients
(n ¼ 2,767)
No HF
Hospitalization
Within 6 Months
(n ¼ 1,963 [71%])
HF Hospitalization
Within 6 Months
(n ¼ 804 [29%])
NT-proBNP
#360 pg/ml
(n ¼ 1,468 [53%])
NT-proBNP
>360 pg/ml
(n ¼ 1,299 [47%])
Age, yrs 72  7 71  7 72  7* 70  7 73  7*
Female 1,694 (61%) 1,185 (60%) 509 (63%) 964 (66%) 730 (56%)*
Racial distribution *
Caucasian 2,565 (93%) 1,800 (92%) 765 (95%) 1,355 (92%) 1,210 (93%)
Black 57 (2%) 40 (2%) 17 (2%) 29 (2%) 28 (2%)
Other 145 (5%) 123 (6%) 22 (3%) 84 (6%) 61 (5%)
Ejection fraction 0.60  0.09 0.60  0.09 0.58  0.09* 0.61  0.09 0.58  0.09*
NYHA functional class * *
III 2,677 (97%) 1,924 (98%) 753 (94%) 1,437 (98%) 1,240 (95%)
IV 90 (3%) 39 (2%) 51 (6%) 31 (2%) 59 (5%)
Heart rate, beats/min 71  10 70  10 74  11* 71  9 72  11*
Blood pressure, mm Hg 136  15 137  15 135  14* 137  14 135  15*
Body mass index, kg/m2 30  5 30  5 29  6 30  5 29  5*
NT-proBNP, pg/ml 323 (130-901) 254 (111-659) 609 (215-1,519)* 136 (73-220) 955 (560-1,687)*
eGFR, l/min/1.73 m2 69  19 70  19 65  19* 74  18 63  19*
Ischemia cause 728 (26%) 510 (26%) 218 (27%) 323 (22%) 405 (31%)*
Hypertension cause 1,756 (64%) 1,271 (65%) 485 (60%)* 1,043 (71%) 713 (55%)*
Medical history
Hypertension 2,455 (89%) 1,750 (89%) 705 (87%) 1,337 (91%) 1,118 (86%)*
Atrial ﬁbrillation 724 (26%) 389 (20%) 335 (42%)* 147 (10%) 577 (44%)*
Diabetes 779 (28%) 533 (27%) 246 (31%) 387 (26%) 392 (30%)*
Stroke 272 (10%) 196 (10%) 76 (10%) 120 (8%) 152 (12%)*
PCI or CABG 375 (14%) 297 (15%) 78 (10%)* 173 (12%) 202 (16%)*
ICD 8 (0%) 4 (0%) 4 (1%) 3 (0%) 5 (0%)
Pacemaker 161 (6%) 98 (5%) 63 (8%)* 36 (3%) 125 (10%)*
Taking medication
Loop-diuretic 2,247 (81%) 1,495 (76%) 752 (94%)* 1,133 (77%) 1,114 (86%)*
ACEi/ARB 696 (25%) 486 (25%) 210 (26%) 327 (22%) 369 (28%)*
Beta-blocker 1,579 (57%) 1,065 (54%) 514 (64%)* 804 (55%) 775 (60%)*
Calcium-channel blocker 1,139 (41%) 843 (43%) 296 (37%)* 666 (45%) 473 (36%)*
Mineralocorticoid antagonists 422 (15%) 210 (11%) 212 (26%)* 161 (11%) 261 (20%)*
Digoxin 378 (14%) 206 (11%) 172 (21%)* 76 (5%) 302 (23%)*
Values are mean  SD, n (%), or median (interquartile range). *p < 0.05 for difference between hospitalization or no hospitalization for heart failure within 6 months, and NT-proBNP
of #360 pg/ml and >360 pg/ml, respectively.
ACEi/ARB ¼ angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; CABG ¼ coronary artery bypass graft; eGFR ¼ estimated glomerular ﬁltration rate; HF ¼ heart failure;
ICD ¼ implantable cardioverter-deﬁbrillator; NT-proBNP ¼ N-terminal proB-type natriuretic peptide; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary intervention.
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481experience the composite outcome of CV death and
HF hospitalization compared to patients with no his-
tory of recent HF hospitalization (HR: 2.71; 95% CI:
2.33 to 3.16; p < 0.01) (Figure 2). In separate analyses
of components of the composite endpoint (Table 2,
Figure 3), recent hospitalization for HF was associated
with a higher risk of both components, although it
seemed to be more strongly associated with HF hos-
pitalization (HR: 3.35; 95% CI: 2.75 to 4.07) than with
risk of CV death (HR: 2.18; 95% CI: 1.79 to 2.65).
Likelihood ratio tests (Table 3) also indicated better
improvement of prediction of HF hospitalization (chi-
square ¼ 141.7) than CV death (chi-square ¼ 58.2)
when recent HF hospitalization was included in the
model.OUTCOMES ACCORDING TO NATRIURETIC PEPTIDE
LEVEL. In a sex- and age-adjusted Cox regression
models, patients with NT-proBNP level >360 pg/ml
were 3 times more likely to experience composite
outcomes of CV death and HF hospitalization than
patients with NT-proBNP level #360 pg/ml (HR: 3.19;
95% CI: 2.68 to 3.71; p < 0.001) (Figure 2).
A higher NT-proBNP level was associated with
similarly higher risks of HF hospitalization (HR:
3.50; 95% CI: 2.78 to 4.40) and CV death (HR: 3.19;
95% CI: 2.54 to 4.00) than an NT-proBNP level of 360
pg/ml or less (Figure 3), and it also yielded similar
improvements in prediction in likelihood ratio tests
(chi-square ¼ 130.1 vs. chi-square ¼ 113.4,
respectively).
TABLE 2 Rates of the Composite Outcome of Cardiovascular Death or Heart Failure Hospitalization, and the 2 Components of the Composite Separately
No. of
Patients
No. of
Events (%)
Event Rate per
100 Patient-Years
Sex- and
Age-Adjusted HR Fully Adjusted HR*
N 2,767 674 (24%) 6.56 (6.08-7.07) -
No HF hospitalization in the last 6 months 1,963 347 (18%) 4.49 (4.04-4.99) 1.00 (ref) 1.00 (ref)
HF hospitalization in the last 6 months 804 327 (41%) 12.78 (11.47-14.24) 2.71 (2.33-3.16) 2.05 (1.74-2.43)
NT-proBNP #360 pg/ml 1,468 183 (13%) 3.04 (2.63-3.52) 1.00 (ref) 1.00 (ref)
NT-proBNP >360 pg/ml 1,299 491 (38%) 11.51 (10.54-12.58) 3.19 (2.68-3.80) 2.25 (1.85-2.74)
Combinations
No HF hosp þ NT-proBNP #360 pg/ml 1,187 120 (10%) 2.42 (2.03-2.90) 1.00 (ref) 1.00 (ref)
No HF hosp þ NT-proBNP >360 pg/ml 776 227 (29%) 8.16 (7.17-9.30) 2.83 (2.26-3.54) 2.24 (1.76-2.88)
HF hosp þ NT-proBNP #360 pg/ml 281 63 (22%) 5.86 (4.58-7.50) 2.42 (1.78-3.29) 2.19 (1.60-3.00)
HF hosp þ NT-proBNP >360 pg/ml 523 264 (50%) 17.79 (15.77-20.07) 6.18 (4.96-7.69) 4.06 (3.16-5.21)
Heart failure hospitalization 2,767 404 (15%) 3.93 (3.56-4.33)
No HF hospitalization in the last 6 months 1,963 185 (9%) 2.40 (2.07-2.77) 1.00 (ref) 1.00 (ref)
HF hospitalization in last 6 months 804 219 (27%) 8.56 (7.50-9.77) 3.35 (2.75-4.07) 2.46 (1.98-3.05)
NT-proBNP #360 pg/ml 1,468 102 (7%) 1.70 (1.40-2.06) 1.00 (ref) 1.00 (ref)
NT-proBNP >360 pg/ml 1299 302 (23%) 7.08 (6.33-7.93) 3.50 (2.78-4.40) 2.29 (1.77-2.97)
Combinations
No HF hosp þ NT-proBNP #360 pg/ml 1,187 57 (5%) 1.15 (0.89-1.50) 1.00 (ref) 1.00 (ref)
No HF hosp þ NT-proBNP >360 pg/ml 776 128 (16%) 4.60 (3.87-5.47) 3.34 (2.44-4.59) 2.46 (1.76-3.44)
HF hosp þ NT-proBNP #360 pg/ml 281 45 (16%) 4.19 (3.12-5.61) 3.59 (2.43-5.31) 3.03 (2.03-4.53)
HF hosp þ NT-proBNP >360 pg/ml 523 174 (33%) 11.73 (10.11-13.61) 8.38 (6.18-11.35) 5.10 (3.62-7.17)
Cardiovascular death 2,767 408 (15%) 3.66 (3.23-4.03) -
No HF hospitalization in the last 6 months 1,963 221 (11%) 2.73 (2.39-3.12) 1.00 (ref) 1.00 (ref)
HF hospitalization in the last 6 months 804 187 (23%) 6.13 (5.31-7.07) 2.18 (1.79-2.65) 1.64 (1.32-2.03)
NT-proBNP #360 pg/ml 1,468 105 (7%) 1.68 (1.39-2.03) 1.00 (ref) 1.00 (ref)
NT-proBNP >360 pg/ml 1,299 303 (23%) 6.20 (5.54-6.93) 3.19 (2.54-4.00) 2.33 (1.81-3.00)
Combinations
No HF hosp þ NT-proBNP #360 pg/ml 1,187 75 (6%) 1.48 (1.18-1.86) 1.00 (ref) 1.00 (ref)
No HF hosp þ NT-proBNP >360 pg/ml 776 146 (19%) 4.82 (4.10-5.67) 2.78 (2.10-3.69) 2.25 (1.67-3.04)
HF hosp þ NT-proBNP #360 pg/ml 281 40 (14%) 2.52 (1.76-3.60) 1.71 (1.12-2.61) 1.56 (1.02-2.40)
HF hosp þ NT-proBNP >360 pg/ml 523 157 (30%) 8.44 (7.22-9.87) 4.99 (3.77-6.60) 3.36 (2.44-4.61)
*Adjusted for age, sex, body mass index, ejection fraction, heart rate, systolic blood pressure, ischemic cause, congestion on radiograph, kidney function, blood urea nitrogen level, neutrophil
count, and history of atrial ﬁbrillation, myocardial infarction, diabetes, and stroke/transient ischemic attack.
HR ¼ hazard ratio; other abbreviations as in Table 1.
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482OUTCOMES ACCORDING TO COMBINATIONS OF THE
2 RISK PREDICTORS. The 2 risk predictors over-
lapped in that 65% of patients with recent hospitali-
zation for HF had NT-proBNP >360 pg/ml, and 40%
of those with NT-proBNP >360 pg/ml also had had a
recent HF hospitalization. We combined the 2 risk
predictors to create 4 distinct risk groups (Table 2).
Event rates for the composite endpoint and HF hos-
pitalization and CV death separately are shown in
Table 2.
For the composite outcome, the highest rate (17.79
events per 100 person-years) was observed in pa-
tients with both an NT-proBNP level >360 pg/ml and
a recent HF hospitalization. Conversely, the lowest
rate (2.42 events per 100 person-years) was ob-
served in patients with neither a NT-proBNP level of
>360 pg/ml nor a recent HF hospitalization. The
composite primary outcome occurred at an interme-
diate rate in patients with one or the other riskpredictor. These patients had a 2- to 3-fold higher
risk of CV death or HF hospitalization, whereas
patients with both a higher NT-proBNP and a recent
HF hospitalization had a 6-fold higher risk of this
outcome (both in comparison to patients with
neither risk predictor) (Figure 3). When the 2 groups
with only 1 of the risk predictors were compared, an
NT-proBNP level >360 pg/ml was associated with a
higher risk of CV death than a recent HF hospitali-
zation in the previous 6 months (HR: 1.63; 95% CI:
1.10 to 2.42; p < 0.01). We found no signiﬁcant dif-
ferences for the risk of HF hospitalization and the
composite outcome, although each risk predictor
alone or combined was more strongly associated
with the risk of HF hospitalization than CV death.
Finally, combining the 2 risk predictors yielded
improved risk prediction compared to each of the
separate, and more so for the risk of HF hospitali-
zation (Table 3).
FIGURE 2 Risk of Composite Outcome
Sex- and age-adjusted risks of composite outcome according to recent heart failure (HF) hospitalization and N-terminal pro–B-type natriuretic
peptide (NT-proBNP) level.
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483OUTCOMES IN FULLY ADJUSTED ANALYSES. In
multivariate Cox regression analyses, with previously
validated covariates such as kidney function, ejection
fraction, and atrial ﬁbrillation, risk estimates associ-
ated with prior HF hospitalization and elevated NT-
proBNP were weakened but remained signiﬁcantly
higher, and the pattern of markedly higher risk in the
presence of both predictors was consistent with the
primary analyses.
SENSITIVITY ANALYSES. Results of the sensitivity
analysis including patients in NYHA II functional
class are shown in the Online Appendix. Results
were entirely consistent with the ﬁndings of the
main analysis. In patients with atrial ﬁbrillation, the
higher risks associated with an elevated NT-proBNP
level, as evaluated by using the fully adjusted haz-
ard ratios, were similar to those in patients without
atrial ﬁbrillation, with the possible exception of CV
death. However, the number of patients with atrial
ﬁbrillation was modest (n ¼ 428), and the 95% CI
intervals around the hazard ratio point estimates
were wide.
DISCUSSION
In this analysis of the I-PRESERVE trial, we found that
both the elevated natriuretic peptide level and the
history of recent HF hospitalization identiﬁed pa-
tients at higher risk for HF hospitalization, CV death,
and the composite of both outcomes. The combina-
tion was an even better predictor of risk.Patients could therefore be divided into 4 distinct
risk groups in which those with neither an elevated
NT-proBNP level nor a recent HF hospitalization were
at lowest risk, those with 1 or the other risk predictor
were at intermediate risk (2- to 3-fold higher than
patients with neither risk predictor), and patients
with both of the predictors were at highest risk (5- to
8-fold higher than patients with neither). NT-proBNP
level was, however, a more powerful individual pre-
dictor of future CV death than recent HF hospitali-
zation. In a subgroup analysis, we found that the risk
associated with a higher NT-proBNP (using the same
cutpoint of 360 pg/ml) were, perhaps surprisingly,
similarly elevated in patients with and without atrial
ﬁbrillation for all outcomes examined, with the
possible exception of CV death. However, because of
the relatively modest number of patients (n ¼ 428)
with atrial ﬁbrillation (and small number of events in
these patients), no deﬁnitive conclusion can be
drawn, and it remains possible that a higher NT-
proBNP threshold would be more appropriate for
risk prediction in these patients than in patients
without atrial ﬁbrillation. In the present study, the
rate of CV death or HF hospitalization in patients with
an elevated NT-proBNP was 11.5 per 100 person-
years. However, in TOPCAT, it is likely that NT-
proBNP was used primarily to determine eligibility
in patients without a recent HF hospitalization (4). In
I-PRESERVE, the rate of CV death or HF hospitaliza-
tion in patients with elevated NT-proBNP but without
a recent HF hospitalization was only 8.2 per 100
FIGURE 3 Risk of Heart Failure Hospitalization and Cardiovascular Death
Sex- and age-adjusted risks of heart failure (HF) hospitalization and cardiovascular death
shown separately, according to recent heart failure hospitalization and N-terminal pro–B-
type natriuretic peptide (NT-proBNP) level.
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484person-years. This rate is similar to that observed in
patients randomized through the natriuretic peptide
stratum into the placebo arm of TOPCAT (8.5 per 100
person-years for the slightly broader primary com-
posite endpoint of CV death, hospitalization for heart
failure, or resuscitation from cardiac arrest).
What differed substantially between the 2 trials
were the event rates in patients enrolled on the basis
of recent HF hospitalization. The rate of CV death or
HF hospitalization in these patients in I-PRESERVE
was 12.8 per 100 patient years. This is considerably
higher than the rate of 6.0 per 100 patient years for the
primary composite endpoint in those enrolled through
the hospitalization stratum in TOPCAT and assigned to
placebo (also 6.0 per 100 person-years in the spi-
ronolactone arm). This comparison assumed that NT-
proBNP level was not available in patients enrolled in
this way in TOPCAT. The CHARM (Candesartan in
Heart failure: Assessment of Reduction in Mortality
andmorbidity)-Preserved study also provided a useful
comparison (10). In that trial, in which NT-proBNP
measurements were not available, the rate of the
composite of CV death or HF hospitalization (the same
composite reported here for I-PRESERVE) was 5.7 per
100 person-years in patients without a history (at anytime) of HF hospitalization and 10.8 per 100 person-
years in those with such a history. In other words, the
rates of the same composite outcomes in patients with
prior HF hospitalization in I-PRESERVE were very
similar to those in CHARM-Preserved, and both were
much higher than that in TOPCAT.
We believe there are 3 potential explanations for
these differences in event rate, all of which have
important implications for the design of future trials
in HF-PEF. One possibility is that, in TOPCAT, hos-
pitalization had to be within 12 months, whereas in I-
Preserve it had to be within 6 months. Following HF
hospitalization, the increased risk of another event
diminishes rapidly over time, although we don’t
believe that a difference of 6 months can explain the
disparity between rates in I-PRESERVE and those in
TOPCAT, especially because a history of HF hospi-
talization at any time in CHARM-Preserved was
associated with an almost doubled rate of the primary
composite outcome compared to no such history.
A second possibility is the protocol wording related
to what was meant by prior hospitalization. In
I-PRESERVE this was stated as: “A subject will be
considered to have been hospitalized for heart failure
if the primary reason for admission was heart failure
and treatment directed speciﬁcally for heart failure,”
whereas in TOPCAT, the wording was: “At least
one hospital admission in the last 12 months for
which heart failure was a major component of the
hospitalization.” This subtle difference may have
been critically important in that the former required
an admission for HF, whereas the latter accepted an
admission with HF (i.e., admissions for another
reason during which patients received treatment for
or had symptoms of HF, e.g., atrial ﬁbrillation). Such
patients may not be at the same risk of future HF
events as those who have had a recent admission
primarily because of HF. Finally, if patients were
enrolled in TOPCAT on the basis of a previous hos-
pitalization, despite knowledge of a low natriuretic
peptide level, this selection bias would have created a
group similar to those in I-PRESERVE with a history of
HF hospitalization but NT-proBNP level #360 pg/ml.
In I-PRESERVE, these individuals had a primary
outcome rate of only 5.9 per 100 patient years
compared with 12.8 per 100 patient years in all pa-
tients with a previous HF hospitalization, regardless
of NT-proBNP level (and a rate of 10.8 per 100 patient
years in CHARM patients with a previous HF hospi-
talization, with unknown natriuretic peptide levels).
Clearly, 5.9 per 100 patient years is very similar to the
rate of 6.0 per 100 patient years for the primary
composite endpoint in those enrolled on the basis of
prior hospitalization in TOPCAT.
TABLE 3 Contribution to Cardiovascular Outcome Prediction
by Recent Heart Failure Hospitalization and NT-proBNP in
I-PRESERVE
Variable
Chi-Square p Value
Effect of adding variables to model
with age and sex only
Composite outcome
HF hospitalization in the last 6 months 158.5 <0.0001
NT-proBNP, 360 pg/ml 190.8 <0.0001
Combined 293.1 <0.0001
HF hospitalization
HF hospitalization in the last 6 months 141.7 <0.0001
NT-proBNP, 360 pg/ml 130.1 <0.0001
Combined 229.4 <0.0001
Cardiovascular death
HF hospitalization in the last 6 months 58.2 <0.0001
NT-proBNP, 360 pg/ml 113.4 <0.0001
Combined 144.6 <0.0001
Effect of adding variable to fully
adjusted model*
Composite outcome
HF hospitalization in the last 6 months 69.5 <0.0001
NT-proBNP, 360 pg/ml 70.3 <0.0001
Combined 127.1 <0.0001
HF hospitalization
HF hospitalization in the last 6 months 65.6 <0.0001
NT-proBNP, 360 pg/ml 41.6 <0.0001
Combined 100.2 <0.0001
Cardiovascular death
HF hospitalization in the last 6 months 19.9 <0.0001
NT-proBNP, 360 pg/ml 46.4 <0.0001
Combined 60.2 <0.0001
*Adjusted for age, sex, body mass index, ejection fraction, heart rate, systolic
blood pressure, ischemic cause, congestion on radiograph, kidney function, blood
urea nitrogen level, neutrophil count, and history of atrial ﬁbrillation, myocardial
infarction, diabetes, and stroke/transient ischemic attack.
Abbreviations as in Table 1.
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485These ﬁndings provide lessons for future trials
conducted in patients with HF-PEF. Ease of recruit-
ment in a clinical trial always reﬂects a balance be-
tween the restriction of the pool of patients available
for recruitment imposed by the inclusion and exclu-
sion criteria, the desire to ensure patients have the
disease in question and the intent to enroll patients at
sufﬁcient risk of the pre-speciﬁed efﬁcacy outcome to
ensure the study has the statistical power to test its
hypothesis. In patients with HF-PEF, a history of HF
hospitalization (especially if recent) and a raised NT-
proBNP level identify patients at higher risk of CV
death or HF hospitalization, although NT-proBNP is a
somewhat stronger predictor, especially of a robust
outcome such as CV mortality. The highest risk pa-
tients are those who have both of these predictors, but
such individuals represented only 19% of the total in
I-PRESERVE. Requiring both of these for inclusion in aHF-PEF trial is likely to be overly restrictive. However,
47% of patients had a high NT-proBNP, 29% had a
history of recent HF hospitalizations, and 57% of pa-
tients had at least 1 of these 2 risk predictors, placing
them at intermediate risk. Using one or the other of
these criteria would greatly expand the pool of avail-
able patients, but with the trade-off of a lower event
rate. Importantly, permitting inclusion of patients on
the basis of prior HF hospitalization despite a known
low natriuretic peptide concentration will select a
relatively low risk group (but one that still has twice
the risk of patients without either risk predictor). This
consideration must be weighed against the difﬁculty
in recruiting HF-PEF patients for clinical trials; it took
36 months to recruit patients for I-PRESERVE and 66
months for TOPCAT. Patients with neither a high
natriuretic peptide level nor a recent HF hospitaliza-
tion have such a low event rate (especially of HF hos-
pitalization) that they probably should not be
recruited in event-driven outcome trials, especially as
itmay also be difﬁcult to be certain of the diagnosis HF-
PEF in such individuals. Deﬁning what is meant by
“prior HF hospitalization” is also likely to be critical,
and investigators and sponsors should consider ex-
amination of source documents to verify such events.
STUDY LIMITATIONS. As with any study of this type,
there are some limitations. I-PRESERVE had speciﬁc
inclusion and exclusion criteria, therefore our ﬁnd-
ings may not be generalized to all patients with HF-
PEF. This was also not a pre-speciﬁed analysis. Our
main analysis excluded patients in NYHA functional
class II because the protocol required such patients to
have a recent history of heart failure hospitalization,
although the sensitivity analysis including all pa-
tients gave similar ﬁndings.
In the present study, we focused on the identiﬁ-
cation of HF-PEF patients at high risk for HF hospi-
talization and CV death. However, it is important to
remember that these are not the only important out-
comes in heart failure and improvement in symptoms
and quality of life are key goals of therapy in HF-PEF.
CONCLUSIONS
Future trials in HF-PEF should require either a higher
natriuretic peptide level or a carefully deﬁned history
of recent HF hospitalization (or both) in order to
identify patients at sufﬁcient risk of future events.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Among
patients with HF-PEF, both recent HFH and an elevated
level of N-terminal pro–B-type natriuretic peptide iden-
tiﬁed patients at high risk for readmission and cardio-
vascular deaths. These risks were greatest when both
factors were present.
TRANSLATIONAL OUTLOOK: Using one or the other
of these criteria would greatly expand the pool of avail-
able patients for clinical trials in HF-PEF while maintain-
ing the event rate. However, the history of HFH should be
veriﬁed.
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